Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2059MR)

This product GTTS-WQ2059MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Canlupfam PDCD1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001314097.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 486213
UniProt ID A0A090BAM7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2059MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6133MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ15498MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ4110MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ11913MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ12837MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ13875MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ10589MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ14897MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW